Cardiovascular risk reduction is a primary treatment goal, given semaglutide's FDA-approved cardiovascular indication
As our understanding of the heterogenous driving factors of OSA evolves, novel treatments are being developed and refined, expanding our therapeutic arsenal
If you have a first-degree relative with medullary thyroid carcinoma or multiple endocrine neoplasia type 2, inform your healthcare provider before starting GLP-1 medications
Since the creation of the company, adhere to the "All for the customers, customer satisfaction is our pursuit" as business philosophy and "Co-Creation, Share the Value" as the purpose of the enterprise
Proc Natl Acad Sci U S A 85:81768180
The provider may be a physician, nurse practitioner, or physician assistant